Eli Lilly’s Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity by CNBC Markets | July 31, 2025 5:15 pm | US Markets Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type 2 diabetes.
